Donostia

• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED … Ended recruitment
  2024-512963-30-00 4 2023-05-24 Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic
• “Randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in patients with hip fracture”. Ended recruitment
  2024-519349-31-00 6 2023-05-17 Hip fracture
• A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Ended recruitment
  2024-514080-25-00 5 2023-04-21 Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
• A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy. Ended recruitment
  2024-511852-42-00 5 2023-01-19 Spinal Muscular Atrophy
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy Ended recruitment
  2022-500090-13-00 4 2022-12-29 Becker Muscular Dystrophy (BMD)
• A global study to evaluate transarterial chemoembolization(TACE) in combination with durvalumab, tremelimumab +/-lenvatinib therapy compared … Ended recruitment
  2023-508701-24-00 5 2022-11-21 Locoregional Hepatocellular Carcinoma (HCC)
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended recruitment
  2024-517008-12-00 5 2022-10-14 Newly-diagnosed multiple myeloma (NDMM)
• DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel … Ended recruitment
  2024-518244-20-01 4 2022-04-25 Urothelial Carcinoma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Trial of different schemes of PM14 alone and in combination with radiotherapy in soft tissue sarcomas and other solid tumors Ended recruitment
  2024-519893-38-00 9 2021-11-23 Soft tissue sarcomas and other solid tumors
• A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Len … Ended recruitment
  2023-505807-21-00 5 2021-11-16 Relapsed/refractory follicular lymphoma
• Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended recruitment
  2023-509843-28-00 5 2021-11-10 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti … Ended recruitment
  2024-516039-28-00 6 2021-09-28 Spontaneous Coronary Artery Dissection.
• AHEAD 3-45 Study: A Clinical Study to Investigate the Effects of BAN2401 in Subjects With Preclinical Alzheimer’s Disease Ended recruitment
  2024-510888-39-00 5 2021-07-21 Early Preclinical Alzheimer’s Disease and Intermediate Amyloid
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease
• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended recruitment
  2022-502705-15-00 5 2021-03-08 High-risk muscle-invasive bladder cancer
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• Clinical trial to compare efficacy and safety of standard chemotherapy versus letrozole plus abemaciclib, chosen randomly, as neoadjuvant th … Ended recruitment
  2024-514395-40-00 4 2020-08-25 High/intermediate risk hormone receptor (HR) positive/human epidermal
• Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended recruitment
  2024-512704-20-00 4 2020-06-22 Unresectable and/or metastatic soft-tissue sarcoma after failure of at
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer

Showing 121–144 of 200 trials